Clinilabs Strengthens Leadership Team to Drive CNS Drug Development Growth
Clinilabs, LLC enhances its executive team with the appointment of David Hagerman as CFO and Jeanine Falinski as SVP of Commercial Development, signaling a strategic push to bolster its position in CNS drug and medical technology development.
Clinilabs, LLC, a prominent contract research organization specializing in central nervous system (CNS) drug and medical technology development, has announced the addition of two seasoned executives to its leadership team. David Hagerman joins as Chief Financial Officer, bringing over 25 years of financial leadership in the life sciences and IT sectors, while Jeanine Falinski assumes the role of Senior Vice President of Commercial Development, leveraging her 20 years of pharmaceutical industry experience. These appointments reflect Clinilabs' strategic focus on enhancing its financial and commercial capabilities to support its growth trajectory in the CNS sector.
The significance of these appointments lies in the critical role Clinilabs plays in advancing therapies for psychiatric, neurological, and substance use disorders, as well as rare CNS diseases. With Hagerman's financial acumen and Falinski's commercial development expertise, Clinilabs is poised to strengthen its service offerings and client engagement, furthering its mission to deliver high-quality, timely, and cost-effective development services. This move not only underscores the company's commitment to leadership excellence but also highlights the growing importance of specialized CROs in accelerating the development of CNS therapies, which have a profound impact on patient outcomes worldwide.